Matthew J. C. Ellis, M.B., B.Chir., Ph.D.

Publications

• Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, Deschryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J
  Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
  Breast Cancer Res Treat 2009 Oct 21; [Epub ahead of print]
• Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ
  Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study.
  Breast Cancer Res Treat 2009 Mar 26; [Epub ahead of print]
• Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA Jr
  Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
  Breast Cancer Res Treat 2009 Feb 18; [Epub ahead of print]
• Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ
  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
  J Clin Oncol 2009 Sep 20;27(27):4530-5
• Ellis MJ, Miller WR, Tao Y, Evans DB, Chaudri Ross HA, Miki Y, Suzuki T, Sasano H
  Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
  Breast Cancer Res Treat 2009 Jul;116(2):371-8
• Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA
  Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
  JAMA 2009 Aug 19;302(7):774-80
• Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF
  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
  Proc Natl Acad Sci U S A 2009 Aug 4;106(31):12909-14
• Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L
  Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
  J Clin Oncol 2009 Jul 20;27(21):3430-6
• Toi M, Sasano H, Ellis MJ
  [Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer.]
  Gan To Kagaku Ryoho 2009 Jun;36(6):1035-42
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO
  Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
  J Natl Cancer Inst 2009 May 20;101(10):736-50
• Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS Jr, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ
  Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
  J Am Coll Surg 2009 May;208(5):906-14
• Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE
  Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
  Cancer Chemother Pharmacol 2009 Feb;63(3):451-8
• Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Janne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA
  A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
  Clin Cancer Res 2009 Apr 1;15(7):2552-8
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS
  Supervised risk predictor of breast cancer based on intrinsic subtypes.
  J Clin Oncol 2009 Mar 10;27(8):1160-7
• Ma CX, Sanchez CG, Ellis MJ
  Predicting endocrine therapy responsiveness in breast cancer.
  Oncology (Williston Park) 2009 Feb;23(2):133-42
• Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA
  PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
  Breast Cancer Res Treat 2009 Feb;113(3):509-17
• Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ
  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
  Cancer Res 2009 May 1;69(9):3955-62
• Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J
  Research issues affecting preoperative systemic therapy for operable breast cancer.
  J Clin Oncol 2008 Feb 10;26(5):806-13
• Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD
  Recommendations for collection and handling of specimens from group breast cancer clinical trials.
  J Clin Oncol 2008 Dec 1;26(34):5638-44
• Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M
  Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
  J Natl Cancer Inst 2008 Oct 1;100(19):1380-8
• Ellis MJ
  Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
  J Natl Cancer Inst 2008 Feb 6;100(3):159-61
• Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C
  ESR1 gene amplification in breast cancer: a common phenomenon?
  Nat Genet 2008 Jul;40(7):806-7; author reply 810-2
• Naughton MJ, Ellis M
  "I'm pregnant and I have breast cancer".
  BMC Cancer 2007 May 30;7:93
• Mullins M, Perreard L, Quackenbush JF, Gauthier N, Bayer S, Ellis M, Parker J, Perou CM, Szabo A, Bernard PS
  Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues.
  Clin Chem 2007 Jul;53(7):1273-9
• Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ
  The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
  Breast Cancer Res Treat 2007 Mar;102(1):43-9
• Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA
  HER2 and response to paclitaxel in node-positive breast cancer.
  N Engl J Med 2007 Oct 11;357(15):1496-506
• Ellis MJ, Ma C
  Letrozole in the neoadjuvant setting: the P024 trial.
  Breast Cancer Res Treat 2007;105 Suppl 1:33-43
• Ellis MJ, Dixon M, Dowsett M, Nagarajan R, Mardis E
  A luminal breast cancer genome atlas: progress and barriers.
  J Steroid Biochem Mol Biol 2007 Aug-Sep;106(1-5):125-9
• Ellis MJ, Crowder R
  "PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy!
  Clin Cancer Res 2007 Oct 1;13(19):5661-2
• Ellis M, Ma C
  Femara and the future: tailoring treatment and combination therapies with Femara.
  Breast Cancer Res Treat 2007;105 Suppl 1:105-15
• Ma CX, Ellis MJ
  Neoadjuvant endocrine therapy for locally advanced breast cancer.
  Semin Oncol 2006 Dec;33(6):650-6
• Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM
  The molecular portraits of breast tumors are conserved across microarray platforms.
  BMC Genomics 2006 Apr 27;7:96
• Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW
  Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
  Clin Cancer Res 2006 Jul 15;12(14 Pt 1):4218-24
• Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L
  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
  Breast Cancer Res 2006;8(6):R66
• Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM
  Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
  J Clin Oncol 2006 Jul 1;24(19):3019-25
• Ellis MJ, Rigden CE
  Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
  Curr Med Res Opin 2006 Dec;22(12):2479-87
• Ellis MJ
  Functional analysis of the breast cancer genome.
  J Clin Oncol 2006 Apr 10;24(11):1649-50
• Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF
  Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
  Clin Cancer Res 2006 Nov 1;12(21):6403-9
• Tao Y, Klause A, Vickers A, Bae K, Ellis M
  Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
  J Steroid Biochem Mol Biol 2005 May;95(1-5):91-5
• Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S
  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
  J Clin Oncol 2005 Apr 10;23(11):2502-12
• Ellis MJ
  Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
  J Clin Oncol 2005 Aug 1;23(22):4842-4
• Crowder RJ, Ellis MJ
  Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
  Breast Cancer Res 2005;7(5):212-4
• Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW
  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
  J Clin Oncol 2005 Mar 1;23(7):1420-30
• Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL
  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
  J Clin Oncol 2005 Aug 10;23(23):5305-13
• Wong ZW, Phillips SJ, Ellis MJ
  Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine.
  Breast J 2004 Jan-Feb;10(1):54-6
• Wong ZW, Ellis MJ
  First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
  Br J Cancer 2004 Jan 12;90(1):20-5
• Wong ZW, Ellis MJ
  Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
  Oncology (Williston Park) 2004 Apr;18(4):411-20; discussion 421, 424, 42
• Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ
  A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
  Clin Cancer Res 2004 Nov 15;10(22):7583-91
• Ellis MJ
  Neoadjuvant endocrine therapy as a drug development strategy.
  Clin Cancer Res 2004 Jan 1;10(1 Pt 2):391S-5S
• Ellis MJ
  Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
  Ann Surg Oncol 2004 Jan;11(1 Suppl):9S-17S
• Ellis M, Ballman K
  Trawling for genes that predict response to breast cancer adjuvant therapy.
  J Clin Oncol 2004 Jun 15;22(12):2267-9
• Ellis M
  Overcoming endocrine therapy resistance by signal transduction inhibition.
  Oncologist 2004;9 Suppl 3:20-6
• Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D
  Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
  Cancer Biol Ther 2004 May;3(5):460-7
• Crowder RJ, Lombardi DP, Ellis MJ
  Successful targeting of ErbB2 receptors-is PTEN the key?
  Cancer Cell 2004 Aug;6(2):103-4
• Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF
  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
  N Engl J Med 2004 Aug 19;351(8):781-91
• Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS
  Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
  Clin Cancer Res 2004 Jan 1;10(1 Pt 2):327S-330S
• Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF
  A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
  Clin Cancer Res 2003 Jan;9(1):124-33
• Schneider SM, Ellis M, Coombs WT, Shonkwiler EL, Folsom LC
  Virtual reality intervention for older women with breast cancer.
  Cyberpsychol Behav 2003 Jun;6(3):301-7
• Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C
  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
  Cancer 2003 Jul 15;98(2):229-38
• Ellis MJ, Rosen E, Dressman H, Marks J
  Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
  J Steroid Biochem Mol Biol 2003 Sep;86(3-5):301-7
• Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR
  Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
  Cancer Res 2003 Oct 1;63(19):6523-31
• Ellis MJ
  Breast cancer gene expression analysis--the case for dynamic profiling.
  Adv Exp Med Biol 2003;532:223-34
• Dowsett M, Ellis MJ
  Role of biologic markers in patient selection and application to disease prevention.
  Am J Clin Oncol 2003 Aug;26(4):S34-9
• Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP
  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase ii trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
  J Clin Oncol 2003 Aug 1;21(15):2889-95
• Shaw HS, Ellis MJ
  Letrozole in the treatment of breast cancer.
  Expert Opin Pharmacother 2002 May;3(5):607-17
• Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A
  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
  J Clin Oncol 2002 Aug 15;20(16):3386-95
• Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y, Clarke R
  Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses.
  Clin Cancer Res 2002 May;8(5):1155-66
• Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M
  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
  J Clin Oncol 2001 Sep 15;19(18):3808-16
• Ellis MJ
  Neoadjuvant endocrine therapy for breast cancer: medical perspectives.
  Clin Cancer Res 2001 Dec;7(12 Suppl):4388s-4391s; discussion 4411s-4412s
• Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M
  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
  Ann Oncol 2001 Nov;12(11):1527-32
• Dressman MA, Walz TM, Lavedan C, Barnes L, Buchholtz S, Kwon I, Ellis MJ, Polymeropoulos MH
  Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies.
  Pharmacogenomics J 2001;1(2):135-41
• Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS
  Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
  Clin Cancer Res 2001 Dec;7(12 Suppl):4335s-4337s; discussion 4411s-4412s
• Ellis MJ
  Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea.
  Cancer Control 2000 Nov-Dec;7(6):557-62
• DaCosta SA, Schumaker LM, Ellis MJ
  Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate?
  J Mammary Gland Biol Neoplasia 2000 Jan;5(1):85-94
• Srivastava RK, Lee YN, Noguchi K, Park YG, Ellis MJ, Jeong JS, Kim SN, Cho-Chung YS
  The RIIbeta regulatory subunit of protein kinase A binds to cAMP response element: an alternative cAMP signaling pathway.
  Proc Natl Acad Sci U S A 1998 Jun 9;95(12):6687-92
• Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ
  The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene.
  Breast Cancer Res Treat 1998 Feb;47(3):269-81
• Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, Siddle K, Harris A
  Insulin-like growth factors in human breast cancer.
  Breast Cancer Res Treat 1998;52(1-3):175-84
• Ellis MJ, Leav BA, Yang Z, Rasmussen A, Pearce A, Zweibel JA, Lippman ME, Cullen KJ
  Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.
  Mol Endocrinol 1996 Mar;10(3):286-97
• Ellis MJ, Lindon AC, Flint KJ, Jones NC, Goodbourn S
  Activating transcription factor-1 is a specific antagonist of the cyclic adenosine 3'.5'-monophosphate (cAMP) response element-binding protein-1-mediated response to cAMP.
  Mol Endocrinol 1995 Feb;9(2):255-65
• Ellis MJ, Hurst HC, Goodbourn S
  A novel cyclic AMP response element-binding protein-1 (CREB-1) splice product may down-regulate CREB-1 activity.
  J Mol Endocrinol 1995 Apr;14(2):191-8
• Ellis MJ, Singer C, Hornby A, Rasmussen A, Cullen KJ
  Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer.
  Breast Cancer Res Treat 1994;31(2-3):249-61
• Ellis MJ, Goodbourn S
  NF-kappa B-independent activation of beta-interferon expression in mouse F9 embryonal carcinoma cells.
  Nucleic Acids Res 1994 Oct 25;22(21):4489-96
• Masson N, Ellis M, Goodbourn S, Lee KA
  Cyclic AMP response element-binding protein and the catalytic subunit of protein kinase A are present in F9 embryonal carcinoma cells but are unable to activate the somatostatin promoter.
  Mol Cell Biol 1992 Mar;12(3):1096-106
• Cullen KJ, Allison A, Martire I, Ellis M, Singer C
  Insulin-like growth factor expression in breast cancer epithelium and stroma.
  Breast Cancer Res Treat 1992;22(1):21-9
• Ellis M, Sikora K
  The current management of testicular cancer.
  Br J Urol 1987 Jan;59(1):2-9
• Ellis M, Sikora K
  Mortality in patients with testicular cancer: report of the Anglia and Trent testicular tumour groups.
  Br Med J (Clin Res Ed) 1986 Mar 8;292(6521):672-4
• Ellis M, Sikora K
  Advances in the management of testicular cancer.
  Drugs Exp Clin Res 1986;12(1-3):219-31
• Dixon AK, Ellis M, Sikora K
  Computed tomography of testicular tumours: distribution of abdominal lymphadenopathy.
  Clin Radiol 1986 Nov;37(6):519-23
• Ellis M, Arno J, Owen-Smith M, Sikora K
  Breast lumps and lymphoma.
  Postgrad Med J 1985 Jun;61(716):521-2
• Ellis M, Hartley L, Sikora K
  Value of follow up in testicular cancer.
  Br Med J (Clin Res Ed) 1984 Nov 24;289(6456):1423